PSMA PET/CT quick procedure guide

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmacology

Background:

• Prostate-Specific Membrane Antigen (PSMA) targeted PET/CT is transforming prostate cancer diagnostics and therapeutics.
• Recent shifts in radiopharmaceutical availability in Spain impact diagnostic procedures and protocols.

Purpose of the Study:

• To develop a clinical guide for the appropriate use of PSMA PET/CT in prostate cancer patients.
• To address frequent clinical scenarios and patient profiles benefiting from PSMA PET/CT.

Main Methods:

• Systematic review of robust evidence on PSMA PET/CT.
• Development of a clinical guide focusing on frequent use cases and patient profiles.
• Consideration of regulatory, cost, and production factors in Spain.

Main Results:

• Established methodology for optimized imaging with PSMA radiopharmaceuticals.
• Recommendations for structured and accurate reporting of metabolic findings with CT.
• Identification of key clinical situations where PSMA PET/CT is crucial.

Conclusions:

• PSMA PET/CT represents a significant advancement in prostate cancer management.
• Clinical guidelines are essential for optimizing the use of this technology amidst evolving access and regulations.
• Standardized reporting enhances the interpretation of PSMA PET/CT findings.